Dainippon Sumitomo drops dementia project at Phase II
This article was originally published in Scrip
Executive Summary
Dainippon Sumitomo Pharma (DSP) has discontinued development of its benzodiazepine partial inverse agonist radequinil (AC-3933). The molecule was in Phase II trials in Japan, the US and Europe for memory impairment in dementia, and acted to stimulate both cholinergic and glutamatergic neurones. However, results from a US study did not meet the criteria for further development, the Japanese company said, without giving further details. DSP recently launched Trerief (zonisamide) in Japan for the treatment of Parkinson's disease symptoms.